Evaluation and Treatment of Chronic Meningitis

The Neurohospitalist

Volumn 4, Issue 4, 2014, Pages 185-195

  Baldwin, Kelly J ^a   Zunt, Joseph R ^b  

^a GEISINGER MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

autoimmune diseases of the nervous system; central nervous system infections; encephalitis; meningitis; meningoencephalitis

Indexed keywords

EID: 84992880599     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874414528940     Document Type: Article

References (51)

1. Mitchell TG Perfect JR. Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995; 8(4):515–548.
2. Mamidi A DeSimone JA Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol. 2002; 8(3):158–167.
3. Powderly WG. Current approach to the acute management of cryptococcal infections. J Infect. 2000; 41(1):18–22.
4. Day J. Cryptococcal meningitis. Pract Neurol. 2004; 4(5):274–285.
5. Seaton RA Verma N Naraqi S Wembri JP Warrell DA. Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg. 1997; 91(1):44–49.
6. Graybill JR Sobel J Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID mycoses study group and AIDS cooperative treatment groups. Clin Infect Dis. 2000; 30(1):47–54.
7. Van der Horst CM Saag MS Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National institute of allergy and infectious diseases mycoses study group and AIDS clinical trials group. N Engl J Med. 1997; 337(1):15–21.
8. Day JN Chau TTH Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013; 368(14):1291–1302.
9. Kabanda T Siedner MJ Klausner JD Muzoora C Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014; 58(1):113–116.
10. Macsween KF Bicanic T Brouwer AE Marsh H Macallan DC Harrison TS. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect. 2005; 51(4):e221–e224.
11. Woodworth GF McGirt MJ Williams MA Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegaly secondary to HIV-associated cryptococcal meningitis. Surg Neurol. 2005; 63(6):529–531.
12. de Vedia L Arechavala A Calderón MI, et al. Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS. Infection. 2013; 41(6):1073–1077.
13. Segal BH Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006; 173(7):707–717.
14. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999; 12(2):310–350.
15. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol. 2002; 33(1):116–124.
16. Jain KK Mittal SK Kuman S Gupta RK. Imaging feature of central nervous system fungal infections. Neurol India. 2007; 55(3):214–250.
17. Viscoli C Machetti M Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002; 40(4):1496–1499.
18. Reinwald M Spiess B Heinz WJ, et al. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspectedinvasiveaspergillosis enhances diagnostic capabilities. J Clin Microbiol. 2013; 51(12):4178–4185.
19. Herbrecht R Denning DW Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347(6):408–415.
20. Thomas A Korb V Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Ther. 2010; 35(1):49–53.
21. Diekema DJ Messer SA Hollis RJ Jones RN Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41(8):3623–3626.
22. Garg RK Sinha MK. Tuberculous meningitis in patients infected with human immunodeficiency virus. J Neurol. 2011; 258(1):3–13.
23. Thwaites GE Chau TT Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004; 42(1):378–379.
24. Stewart SM. The bacteriological diagnosis of tuberculous meningitis. J Clin Pathol. 1953; 6(3):241–242.
25. Cecchini D Ambrosioni J Brezzo C, et al. Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis. 2009; 13(2):269–271.
26. Jarvis JN Meintjes G Williams A Brown Y Crede T Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010; 10: 67.
27. Thwaites GE Caws M Chau TT, et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified Mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol. 2004; 42(3):996–1002.
28. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programs. 3rd ed. Geneva, Switzerland: World Health Organization; 2002.
29. Prasad K Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2008;(1):CD002244.
30. Pepper DJ Marais S Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009; 48(11):e96–e107.
31. Flood JM Weinstock HS Guroy ME Bayne L Simon RP Bolan G. Neurosyphilis during the AIDS epidemic, San Francisco 1985-1992. J Infect Dis. 1998; 177(4):931–940.
32. Moore JE Hopkins HH. Asymptomatic neurosyphilis: VI. The prognosis of early and late asymptomatic neurosyphilis. JAMA. 1930; 95(22):1637–1641.
33. Marra CM Tantalo LC Maxwell CL Ho EL Sahi SK Jones T. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex Transm Dis. 2012; 39(6):453–457.
34. Marra CM Tantalo LC Maxwell CL Dougherty K Wood B. Alternative cerebrospinal fluid tests to diagnose neurosyphilis in HIV-infected individuals. Neurology. 2004; 63(1):85–88.
35. Rolfs RT Joesoef MR Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patient with and without human immunodeficiency virus infection. The Syphilis and HIV study group. N Engl J Med. 1997; 337(5):307–314.
36. Centers for Disease Control and Prevention. 2010 Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep. 2010; 59(RR 12):1–110.
37. Joseph FJ Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007; 7(4):234–244.
38. Gascón-Bayarri J Mañá J Martínez-Yélamos S Murillo O Reñé R Rubio F. Neurosarcoidosis: report of 30 cases and a literature survey. Eur J Intern Med. 2011; 22(6):e125–e32.
39. Wengert O Rothenfusser-Korber E Vollrath B, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci. 2013; 335(1-2):124–130.
40. Ginat DT Dhillon G Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011; 1: 15.
41. Nozaki K Judson MA. Neurosarcoidosis. Curr Treat Options Neurol. 2013; 15(4):492–504.
42. Kim JM Kim KJ Yoon HS, et al. Meningitis in Korean patients with systemic lupus erythematosus: analysis of demographics, clinical features and outcomes; experience from affiliated hospitals of the Catholic University of Korea. Lupus. 2011; 20(5):531–536.
43. Joseph FG Lammie GA Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007; 69(7):644–654.
44. Bertsias GK Ioannidis JP Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010; 69(12):2074–2082.
45. Fragoso Loyo H Cabiedes J Orozco-Narvaez A, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One. 2008; 3(10):e3347.
46. Hajj-Ali RA Singhal AB Benseler S Molloy E Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. 2011; 10(6):561–572.
47. Alrawi A Trobe JD Blaivas M Musch DC. Brain biopsy in primary angiitis of the central nervous system. Neurology. 1999; 53(4):858–860.
48. Hajj-Ali RA. Primary angiitis of the central nervous system: differential diagnosis and treatment. Best Pract Res Clin Rheumatol. 2010; 24(3):413–426.
49. Glass JP Melamed M Chernik NL, et al. Malignant cells in the cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979; 29(20):1369–1375.
50. Chamberlain MC. Neoplastic meningitis. Oncologist 2008; 13(9):967–977.
51. Smith JE Aksamit AJ Jr. Outcome of chronic idiopathic meningitis. Mayo Clin Proc. 1994; 69(6):548–556.